Article
Santen submits NDA for levofloxacin 1.5%
Santen Pharmaceuticals Co. filed a New Drug Application with the FDAon Monday for levofloxacin 1.5%, the company's new ocular anti-infectivedrug.The larger concentration of Levofloxacin is a potent, broad-spectrumantibiotic. The company reports that Levofloxacin's higher solubility, atneutral pH, allows the drug to be formulated at a higher concentration thanother fluoroquinolones on the market.
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Related Videos
Related Content
